Circulating Inflammatory Biomarkers Level Before Thrombolysis for Acute Ischemic Stroke Predicts Symptomatic Intracerebral Hemorrhage.
Lingzhi Li,Ziping Han,Zhenhong Yang,Qingfeng Ma,Haiping Zhao,Rongliang Wang,Junfen Fan,Liyuan Zhong,Yue Hu,Ping Liu,Yangmin Zheng,Yumin Luo
DOI: https://doi.org/10.14336/ad.2022.0608
2023-01-01
Aging and Disease
Abstract:Recombinant tissue plasminogen activator (rtPA) remains the only therapeutic agent approved for salvaging the penumbra through reperfusion after acute ischemic stroke (AIS) [1]. It effectively dissolves thrombi within 4.5 h after stroke onset, but it increases the risk of cerebral hemorrhage and malignant cerebral edema in AIS patients [2]. Thrombosis and inflammation are highly intertwined contributors to the pathophysiologic processes of stroke.
What problem does this paper attempt to address?